Eli Lilly ended 2019 with a win in its long-running legal battle to prevent generics of its big-selling cancer drug Alimta from reaching the US market.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,